Peripheral arterial disease is estimated to affect more than 200 million people worldwide.
Although more than 50% of those affected are asymptomatic, it accounts for 3%-4% of …

Background Significant race and sex disparities exist in the prevalence, diagnosis, and
outcomes of peripheral artery disease (PAD). However, clinical trials evaluating treatments …

Background: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …

Objectives This study aimed to investigate the 1-year risk of restenosis and aneurysmal
degeneration and explore the associated factors after femoropopliteal implantation of …

Background Although clinical trials have reported favorable outcomes after drug‐coated
balloon (DCB) therapy for femoropopliteal lesions, their real‐world performance and …

Abstract Purpose of Review Peripheral artery disease (PAD) is an increasingly prevalent but
frequently underdiagnosed condition that can be associated with high rates of morbidity and …

Background In patients with intermittent claudication (IC), short-term amputation rates from
clinical trial data following lower extremity femoropopliteal (FP) peripheral vascular …

In an aging population with a rising incidence of peripheral artery disease, endovascular
therapy is a favorable alternative to open surgical bypass. As a minimally invasive approach …

Objective Stent grafts (SG) and drug eluting stents (DES) have emerged to combat intimal
hyperplasia. It remains unclear which type of stent yields superior outcomes in …

Background Treatment with a fluoropolymer-based drug-eluting stent (FP-DES has been
widely applied to the contemporary femoropopliteal practice with durable outcomes …